Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Treating LEMS: Medications and Safety

At a Glance

Amifampridine is the main medicine used to improve strength in LEMS, but it requires careful prescribing because seizures can occur even at recommended doses. Other care may include immune treatments, treatment of an underlying cancer, and close neurology and oncology monitoring.

The primary symptomatic treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) is a medication called amifampridine (also known as 3,4-diaminopyridine or 3,4-DAP) [1][2]. This drug works by blocking potassium channels on the nerve ending, which keeps the nerve “active” longer, allowing more calcium to enter and release the chemical signal your muscles need to move [3].

Dosing and Administration

Because amifampridine is short-acting, it is taken in divided doses throughout the day.

  • Titration: Most patients start at a low dose (e.g., 15 mg per day in divided doses) and slowly increase every few days under strict medical guidance until the best balance of strength and side effects is found [4][5].
  • Maximum Limits: The maximum dose varies by specific product label and country (often capped around 80 mg per day for adults) [2][5]. Only your prescriber should change your dose. Never “double up” on a missed dose.
  • Organ Function: Your kidney and liver function heavily influence how your body clears this drug. If you have renal or hepatic impairment, your doctor will adjust your dose accordingly.

Safety and Serious Precautions

While highly effective, amifampridine requires careful monitoring.

  • Seizure Risk: Amifampridine can trigger seizures, and this risk exists at prescribed doses, not just when exceeding maximum limits [6][7]. It is strictly contraindicated if you have a history of seizures. You must also avoid taking other aminopyridines simultaneously and have a pharmacist or neurologist review all your medications for any that lower the seizure threshold.
  • Cardiac Monitoring (ECG): Some product labels advise that the drug may affect the heart’s electrical rhythm (the PR interval). Depending on your specific medication formulation, cardiac history, and other concomitant medicines, your clinician may recommend periodic ECG monitoring [8][7].
  • Common Side Effects: Many patients experience a tingling or “pins and needles” sensation (paresthesia) in the face, fingers, or toes, as well as stomach upset [6][5]. While common, severe, new, or rapidly worsening tingling should always be reported to your doctor.

Secondary Options and Immunosuppression

If amifampridine alone does not provide enough strength, your care team may coordinate other treatments.

  • Pyridostigmine: This drug can sometimes be added to amifampridine to help “boost” the signal at the muscle [9][10].
  • Immunosuppressants: For persistent or severe symptoms, drugs that quiet the immune system—such as prednisone or azathioprine—may be used to reduce antibody production [1][11]. If you have cancer-associated LEMS, immunosuppression requires close oncology input.
  • Rescue Therapies: In severe cases where strength or breathing is failing rapidly, IVIG (intravenous immunoglobulin) or plasma exchange (plasmapheresis) can provide a temporary reduction of antibodies in the blood [12][13].

A Warning: Immune Checkpoint Inhibitors (ICIs)

If you are treated for lung cancer, you may be offered a type of immunotherapy called an Immune Checkpoint Inhibitor (e.g., nivolumab, atezolizumab).
Use caution: While these are effective cancer treatments, neurologic immune-related worsening—including severe exacerbation of LEMS and respiratory failure—has been reported [14][15]. This does not mean you must automatically refuse these therapies. Instead, it requires an individualized risk assessment, informed consent, and very close coordination and monitoring between your oncology and neurology teams [16][17].

Coordinated Care Strategy

Treatment for LEMS is not a rigid, sequential path, but rather a coordinated, concurrent effort:

  1. Symptomatic Management: Starting and optimizing amifampridine to improve daily function.
  2. Cancer Therapy: If a tumor is found, treating the cancer is a priority and often significantly improves LEMS [18].
  3. Ongoing Support: Utilizing immunosuppressants, swallowing/respiratory support, and physical rehabilitation simultaneously based on your severity and treatment goals [1].

Common questions in this guide

How is Lambert-Eaton syndrome usually treated?
Amifampridine is the main medicine used to improve muscle strength in LEMS by helping nerves send more signals to muscles. Doctors may add pyridostigmine, immune-suppressing medicines, IVIG, or plasma exchange depending on symptom severity, and treating an underlying cancer is an important part of care.
How should I take amifampridine safely for LEMS?
Amifampridine is usually taken in divided doses, starting at a low dose and increasing gradually under the prescriber's guidance. The maximum dose depends on the product, country, and your kidney or liver function; never change the dose yourself or double a missed dose.
Can amifampridine cause seizures?
Yes, seizures can occur even when amifampridine is taken at a prescribed dose, so it should not be used by people with a history of seizures. Do not take other aminopyridines, and ask a pharmacist or neurologist to review medicines that could increase seizure risk.
What side effects and heart precautions matter with amifampridine?
Tingling or pins-and-needles sensations and stomach upset are common side effects. Severe, new, or rapidly worsening tingling should be reported to your doctor, and your clinician may recommend an ECG, or heart rhythm test, based on your medication formulation, heart history, and other medicines.
What treatments may help if amifampridine is not enough?
For persistent or severe weakness, the care team may add pyridostigmine or consider medicines such as prednisone or azathioprine that reduce immune activity. IVIG or plasma exchange may provide temporary help when weakness or breathing problems worsen rapidly.
Is lung cancer immunotherapy safe if I have LEMS?
Immune checkpoint inhibitors such as nivolumab or atezolizumab can worsen LEMS, and severe worsening with respiratory failure has been reported. These medicines are not automatically ruled out, but they require an individualized risk assessment, informed consent, and close monitoring by oncology and neurology teams.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my exact starting dose of amifampridine, and what is the plan for safe titration?
  2. 2.Since I have [insert kidney/heart/seizure history], how does that affect my medication choices and monitoring plan?
  3. 3.If I don't see enough improvement on symptomatic medications, at what point would we consider immunosuppressants like azathioprine or IVIG?
  4. 4.Can you or a pharmacist review my full list of prescriptions, over-the-counter drugs, and supplements to check for any that might lower my seizure threshold?
  5. 5.If I need treatment with an immune checkpoint inhibitor for cancer, how will we coordinate oncology and neurology to monitor for a LEMS flare?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

    Schoser B, Eymard B, Datt J, Mantegazza R

    Journal of neurology 2017; (264(9)):1854-1863 doi:10.1007/s00415-017-8541-9.

    PMID: 28608304
  2. 2

    Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

    Hatanaka Y, Mori-Yoshimura M, Utsugisawa K, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(24)):3493-3501 doi:10.2169/internalmedicine.5363-25.

    PMID: 40533232
  3. 3

    Lambert-Eaton Myasthenic syndrome: early diagnosis is key.

    Ivanovski T, Miralles F

    Degenerative neurological and neuromuscular disease 2019; (9()):27-37 doi:10.2147/DNND.S192588.

    PMID: 31191084
  4. 4

    Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.

    Shieh P, Sharma K, Kohrman B, Oh SJ

    Journal of clinical neuromuscular disease 2019; (20(3)):111-119 doi:10.1097/CND.0000000000000239.

    PMID: 30801481
  5. 5

    Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.

    Oh SJ

    Expert review of clinical immunology 2019; (15(10)):991-1007 doi:10.1080/1744666X.2020.1670061.

    PMID: 31533480
  6. 6

    Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.

    Haroldsen PE, Musson DG, Hanson B, et al.

    Clinical therapeutics 2015; (37(7)):1555-63.

    PMID: 26101174
  7. 7

    Amifampridine overdose leading to refractory status epilepticus.

    Gooley B, Willenbring B, Wilkinson J

    The American journal of emergency medicine 2024; (80()):231.e1-231.e2 doi:10.1016/j.ajem.2024.04.023.

    PMID: 38693021
  8. 8

    Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers.

    Ishida N, Kobayashi E, Kondo Y, et al.

    International journal of clinical pharmacology and therapeutics 2015; (53(8)):674-80 doi:10.5414/CP202133.

    PMID: 26152130
  9. 9

    Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors.

    Yamasaki H, Futamura N, Funakawa I, et al.

    Internal medicine (Tokyo, Japan) 2022; (61(7)):1063-1065 doi:10.2169/internalmedicine.7902-21.

    PMID: 34544947
  10. 10

    Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome.

    Oh SJ

    Journal of clinical neurology (Seoul, Korea) 2024; (20(4)):353-361 doi:10.3988/jcn.2024.0018.

    PMID: 38951970
  11. 11

    Tubular aggregates in autoimmune Lambert-Eaton myasthenic syndrome.

    Cordts I, Funk F, Schulz JB, et al.

    Neuromuscular disorders : NMD 2016; (26(12)):880-884 doi:10.1016/j.nmd.2016.09.011.

    PMID: 27816328
  12. 12

    Early Induction of IVIg Improved the Performance Status and Enabled Chemotherapy Initiation in PCD-LEMS: A Case Report.

    Tanaka T, Kitamura A, Tamura R, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.7251-26.

    PMID: 42618261
  13. 13

    A Rare Case of Lambert-Eaton Myasthenia Syndrome With Dysphasia and Dysarthria.

    Harimohan H, Yasonova M, Sukkar M, Sabetian K

    Cureus 2025; (17(6)):e86700 doi:10.7759/cureus.86700.

    PMID: 40574941
  14. 14

    Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.

    Seligman C, Chang YM, Luo J, Garden OA

    Frontiers in neurology 2022; (13()):1004810 doi:10.3389/fneur.2022.1004810.

    PMID: 36698907
  15. 15

    Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma.

    Dohrn MF, Schöne U, Küppers C, et al.

    Neurological research and practice 2020; (2()):52 doi:10.1186/s42466-020-00099-5.

    PMID: 33324947
  16. 16

    Diaphragmatic Palsy Due to a Paraneoplastic Autoimmune Syndrome Revealed by Checkpoint Inhibitors.

    Destival JB, Michot JM, Cauquil C, et al.

    Reports (MDPI) 2024; (7(4)) doi:10.3390/reports7040084.

    PMID: 40757701
  17. 17

    Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.

    Machiyama H, Minami S

    Journal of medical cases 2023; (14(2)):71-75 doi:10.14740/jmc4043.

    PMID: 36896371
  18. 18

    Paraneoplastic Lambert-Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review.

    Preßler H, Haddy I, Daugherty C, et al.

    Neurological research and practice 2025; (7(1)):95 doi:10.1186/s42466-025-00453-5.

    PMID: 41361909

This page explains LEMS medications and safety considerations for informational purposes only and does not constitute medical advice. Your neurologist, pharmacist, and oncology team should individualize treatment, dosing, and monitoring.

Get notified when new evidence is published on Lambert-Eaton myasthenic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.